Sun Pharma has received approval from the Drugs Controller General of India to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 receptor ...

India has begun the first wave of regulatory approvals for generic semaglutide, as domestic drugmakers secure CDSCO ...

India's top drug maker Sun Pharmaceutical Industries has announced today the launch of a generic version of semaglutide, the ...

Sun Pharma receives DCGI approval to launch generic semaglutide injection, Noveltreat, for weight management in India.

Noveltreat to be available in five dose strengths of 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL and 2.4 ...

DCGI approval to Sun Pharma comes amid an ongoing patent dispute with Novo Nordisk in the Delhi High Court. The case relates ...

Sun Pharma has received DCGI approval for generic semaglutide for weight management and will launch Noveltreat after the ...

Eli Lilly Weight Loss Drug in India: US pharmaceutical giant Eli Lilly has launched its much-anticipated weight loss and diabetes management drug, Mounjaro, in India. Priced significantly lower than ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for weight management as an adjunct to a reduced-calorie diet and increased physical activity.